Articles

According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab. Read More ›

Historically, therapies for patients with MM included high-dose dexamethasone, alkylating agents, and autologous stem cell transplantation. In the late 1990s, a new era in myeloma treatment began with the introduction of the immunomodulatory drug (IMiD) thalidomide, followed by subsequent development of the proteasome inhibitors bortezomib and carfilzomib, and the next-generation IMiDs lenalidomide and pomalidomide. Read More ›

Although the 5-year survival rate for multiple myeloma is less than 50%, this type of cancer has witnessed a resurgence of drug therapies. Read More ›

Second-line therapy with trastuzumab deruxtecan (Enhertu; T-DXd) extended progression-free survival (PFS) and improved objective response rate (ORR) versus trastuzumab emtansine (Kadcyla; T-DM1) in women with HER2-positive metastatic breast cancer, including those with stable brain metastasis at baseline, according to a subgroup analysis of a phase 3 clinical trial. Read More ›

Both this retrospective analysis of the ICARIA-MM study data and the phase 1b TCD14079 study data aimed to evaluate the efficacy of isatuximab (Isa) with pomalidomide-dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM) with the gain(1q21) chromosomal abnormality. Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM) at target dose levels of ≥150 × 10⁶ chimeric antigen receptor (CAR)+ T-cells, the updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, idecabtagene vicleucel. Read More ›

In heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), preliminary results from the phase 1b/2 CARTITUDE-1 study show early, deep, and durable responses with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) and a safety profile consistent with prior studies. Read More ›

Favorable efficacy and manageable safety are shown in the updated analysis of the phase 1 study of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM). This analysis supports the planned phase 2 monotherapy trial at 1500 µg/kg administered subcutaneously. Read More ›

This phase 1, first-in-human study evaluates patients with relapsed/refractory multiple myeloma (RRMM) who are heavily pretreated with REGN5458. Results of this updated analysis are consistent with those of previous findings showing an acceptable safety profile and deep and durable responses. The phase 2 portion of the study is further progressing. Read More ›

This primary analysis evaluated patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior lines of therapy, including lenalidomide (Len) and a proteasome inhibitor (PI). Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab (DARA) plus Pd reduced the risk of disease progression and death without additional safety signals. Read More ›